Efficacy of Endoscopic Ultrasound Radiofrequency Ablation in the Treatment of Pancreatic Tumor: Is It Ready for Prime Time? A Systematic Review and Meta-Analysis 7

Authors

Amaninder Dhaliwal MD, University of Nebraska Medical Center
Banreet Dhindsa MD, University of Nevada, Las VegasFollow
Jacqueline Choa MD, University of Nevada, Las VegasFollow
Robin Jindal MBBS, State University of New York at Buffalo
Harlan Sayles MS, University of Nebraska Medical Center
Harmeet Mashiana MD, University of Nebraska Medical Center
Sindhura Kolli MD, Brooklyn Hospital Center
Rajani Rangray MD, Creighton University Medical Center
Ishfaq Bhat MD, University of Nebraska Medical Center
Shailender Singh MD, University of Nebraska Medical Center
Douglas G. Adler MD; FACG, University of Utah School of Medicine

Document Type

Abstract

Publication Date

10-1-2019

Publication Title

American Journal of Gastroenterology

Volume

114

First page number:

S4

Abstract

Endoscopic ultrasound radiofrequency ablation (EUS-RFA) is the newer technique, which is minimally invasive, more selective and safer in patients with unresectable pancreatic ductal adenocarcinoma (PDAC). We did systematic review and meta-analysis to evaluate the efficacy of EUS-RFA in the treatment of unresectable PDAC, pancreatic neuroendocrine tumors (PNENs) and other pancreatic tumors.

Disciplines

Endocrinology

Language

English

Repository Citation

Dhaliwal, A., Dhindsa, B., Choa, J., Jindal, R., Sayles, H., Mashiana, H., Kolli, S., Rangray, R., Bhat, I., Singh, S., Adler, D. G. (2019). Efficacy of Endoscopic Ultrasound Radiofrequency Ablation in the Treatment of Pancreatic Tumor: Is It Ready for Prime Time? A Systematic Review and Meta-Analysis 7. American Journal of Gastroenterology, 114 S4.
http://dx.doi.org/10.14309/01.ajg.0000589560.18183.05